Breakthrough in drug trial offers hope for heart attack patients
2010-09-13
(Press-News.org) New findings from a major drug trial have brought experts a step closer to developing a drug which could prevent thousands of British deaths from heart attacks.
Dr Robert Storey, Reader at the University of Sheffield and Consultant Cardiologist at Sheffield Teaching Hospitals, was the UK lead for international trials of a new drug, ticagrelor, which have been taking place over the last six years.
The new findings from one of these studies, the ONSET/OFFSET study, revealed that the platelet function in patients taking ticagrelor recovered much quicker after the drug is stopped, compared to the current gold standard drug, clopidogrel. This study also confirmed that breathlessness occurs as a side effect of ticagrelor but this is not associated with any harmful effects on lung or heart function.
The findings also include a new analysis of a previous trial looking at ticagrelor. This new examination of the PLATO trial, which was completed last year, shows that ticagrelor prevents 1 in 5 deaths after a heart attack, and patients who develop the adverse effect of breathlessness with ticagrelor still benefit from a lower risk of death compared to patients treated with clopidogrel for one year following a heart attack.
Dr Storey presented these latest results at the European Society of Cardiology (ESC) Congress 2010 on 29 August 2010 and was also involved in a 10,000 patient genetic substudy of the PLATO trial that was presented at the same time and published in The Lancet. This confirmed that patients treated with clopidogrel, who have a genetic variant that reduces the effect of this drug have a slightly higher risk following heart attack but ticagrelor is not affected by this variant and is still more effective than clopidogrel, regardless of a patient's genetic make-up.
Dr Storey has been involved with the development of the new drug, ticagrelor, for the past 12 years. 90 patients from Sheffield, with acute coronary syndrome, were recruited for the PLATO trial, which involved over 18,000 cardiac patients worldwide.
The latest findings come days before World Heart Day (26 September 2010) which celebrates progress in heart health. The study has previously shown for every 1,000 patients treated for one year with ticagrelor instead of clopidogrel, there would be 14 fewer deaths or 11 fewer heart attacks without an increase in bleeding problems.
Dr Storey said: "The latest results on ticagrelor reinforce the positive data from the PLATO trial and suggest that ticagrelor has the potential to improve the quality of care and save many lives in the year following a heart attack, regardless of adverse effects or genetic differences in the response to clopidogrel."
INFORMATION: END
ELSE PRESS RELEASES FROM THIS DATE:
2010-09-13
Stroke patients who were left partially paralysed found that their condition improved after they received a simple and non-invasive method of brain stimulation, according to research in the September issue of the European Journal of Neurology.
Researchers from the Ain Shams University in Cairo, Egypt, studied 60 patients with ischaemic stroke - where the blood supply is reduced to the brain - who had been left with mild to moderate muscle weakness down one side of their body.
Twenty of the randomly assigned treatment group received repetitive transcranial magnetic ...
2010-09-13
CAMBRIDGE, Mass. - Using carbon nanotubes (hollow tubes of carbon atoms), MIT chemical engineers have found a way to concentrate solar energy 100 times more than a regular photovoltaic cell. Such nanotubes could form antennas that capture and focus light energy, potentially allowing much smaller and more powerful solar arrays.
"Instead of having your whole roof be a photovoltaic cell, you could have little spots that were tiny photovoltaic cells, with antennas that would drive photons into them," says Michael Strano, the Charles and Hilda Roddey Associate Professor of ...
2010-09-13
Berkeley – Engineers at the University of California, Berkeley, have developed a pressure-sensitive electronic material from semiconductor nanowires that could one day give new meaning to the term "thin-skinned."
"The idea is to have a material that functions like the human skin, which means incorporating the ability to feel and touch objects," said Ali Javey, associate professor of electrical engineering and computer sciences and head of the UC Berkeley research team developing the artificial skin.
The artificial skin, dubbed "e-skin" by the UC Berkeley researchers, ...
2010-09-13
Although overall mortality from cancer is decreasing in the European Union, its incidence increased by almost 20%, from 2.1 million new cases in 2002 to 2.5 million in 2008, says a special issue [1] of the European Journal of Cancer (the official journal of ECCO – the European CanCer Organisation) on cancer prevention, published today (Monday 13 September).
The current economic crisis threatens to affect cancer incidence in a number of areas, says a paper by Dr. José M. Martin-Moreno from the University of Valencia, Spain, and colleagues. Public donations to cancer ...
2010-09-13
LA JOLLA, CA – September 9, 2010 – Scientists from The Scripps Research Institute have solved a long-standing mystery of how cells conduct "quality control" to eliminate the toxic effects of a certain kind of error in protein production. The findings may lead to a better understanding of a host of neurodegenerative diseases.
The research was published in an advance, online issue of the journal Nature on September 12, 2010.
"It is exciting because we are dealing not only with a process that is clearly relevant for physiology and disease," said Scripps Research Assistant ...
2010-09-13
DURHAM, N.C. -- Myopia (nearsightedness) is the most common eye disorder in the world and becoming more common, yet little is known about its genetic underpinnings.
Scientists at Duke University Medical Center, in conjunction with several other groups, have uncovered a gene associated with myopia in Caucasian people from several different regions, including Dutch, British and Australian subjects.
Their work was published in Nature Genetics online on Sunday, Sept. 12.
Myopia happens when the focal point of an image falls just short of the retina at the rear of the ...
2010-09-13
A MRSA infection with a reduced susceptibility to the potent antibiotic drug vancomycin is linked to high mortality, according to a Henry Ford Hospital study.
Researchers found that patients who contracted a MRSA infection with heteroresistance, called hVISA, stayed in the hospital longer, were more likely to have the infection return after 90 days, and were twice as likely to die from it after 90 days than patients who do not have hVISA.
The study is being presented Sunday at the 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy in Boston.
"Based ...
2010-09-13
Men aged 55 to 74 years who have low baseline blood levels of prostate specific antigen (PSA) are not likely to benefit from further screening and treatment. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. The aim of the study is to help physicians and patients weigh the pros and cons of prostate cancer screening and early detection.
Prostate cancer is the most commonly diagnosed malignancy and the third leading cause of death from cancer in men in Western countries. While a man in the United ...
2010-09-13
A new study conducted by researchers at the Center for Injury Research and Policy at Nationwide Children's Hospital examined basketball-related injuries treated in emergency departments among children and adolescents between the ages of 5 and 19 from 1997 to 2007. According to the study, more than 4 million basketball-related injuries were treated in emergency departments during the 11-year study. While the number of injuries decreased 22 percent over the course of the study, the average number of injuries per year (375,350) remained high.
Data from the study, being ...
2010-09-13
Two multi-award winning green IT companies, VeryPC and MiniFrame have today announced their collaboration to produce a range of high performance, energy saving solutions to desktop virtualization. The GreenHive for SoftXpand range combines energy efficient software expertise of MiniFrame with the life-cycle engineering and energy calibrating hardware ingenuity of VeryPC.
Close collaboration between the two companies allows VeryPC to optimize and produce a dedicated appliance for MiniFrame's award-winning SoftXpand multi-user software. VeryPC GreenHives enhance the SoftXpand ...
LAST 30 PRESS RELEASES:
[Press-News.org] Breakthrough in drug trial offers hope for heart attack patients
